Einsatzmöglichkeiten der Gentherapie in der HNO-Heilkunde

Literatur

• 1 Weber B L. Cancer genomics.  Cancer Cell. 2002;  1 37
• 2 Fey M F. Impact of the Human Genome project on the clinical management of sporadic cancers.  Lancet Oncol. 2002;  3 349-356
• 3 Wollenberg B, Naujoks K, Kastenbauer E. Somatic gene therapy in squamous epithelial carcinomas of the head-neck area.  Laryngorhinootologie. 1996;  75 356-362
• 4 Wu C L, Garry M G, Zollo R A, Yang J. Gene therapy for the management of pain; Part I: Methods and strategies.  Anesthesiology. 2001;  94 1119-1132
• 5 Wu C L, Garry M G, Zollo R A, Yang J. Gene therapy for the management of pain; Part II: Molecular targets.  Anesthesiology. 2001;  95 216-240
• 6 Kanzaki S, Kawamoto K, Oh S H, Stover T, Suzuki M, Ishimoto S, Yagi M, Miller J M, Lomax M I, Raphael Y. From gene identification to gene therapy.  Audiol Neurootol. 2002;  7 161-164
• 7 Kawamoto K, Oh S H, Kanzaki S, Brown N, Raphael Y. The functional and structural outcome of inner ear gene transfer via the vestibular and cochlear fluids in mice.  Mol Ther. 2001;  4 575-585
• 8 Kanzaki S, Ogawa K, Camper S A, Raphael Y. Transgene expression in neonatal mouse inner ear explants mediated by first and advanced generation adenovirus vectors.  Hear Res. 2002;  169 112-120
• 9 Stover T, Kawamoto K, Kanzaki S, Raphael Y. Feasibility of inner ear gene transfer after middle ear administration of an adenovirus vector.  Laryngorhinootologie. 2001;  80 431-435
• 10 Luebke A E, Steiger J D, Hodges B L, Amalfitano A. A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function.  Gene Ther. 2001;  8 789-794
• 11 Bonadio J, Woo S L, High K, Ghivizzani S C, Schaffer D. Genetic approaches to tissue engineering: breakhout session summary.  Ann N Y Acad Sci. 2002;  961 71-72
• 12 Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines.  Curr Gene Ther. 2001;  1 31-52
• 13 McCormick F, Jin X, Bookstein R, Wills K, Avanzini J, Tsai V, LaFace D, Terracina G, Shi B, Nielsen L L. Cancer gene therapy: fringe or cutting edge?.  Nat Rev Cancer. 2001;  1 130-141
• 14 Kirn D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?.  Gene Ther. 2001;  8 89-98
• 15 Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landes S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.  J Clin Oncol. 2001;  19 289-298
• 16 Merritt J A, Roth J A, Logothetis C J. Clinical evaluation of adenoviralmediated p53 gene transfer: review of INGN 201 studies.  Semin Oncol. 2001;  28 105-114
• 17 Fukui T, Hayashi Y, Kagami H, Yamamoto N, Fukuhara H, Tohnai I, Ueda M, Mizuno M, Yoshida J. Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector.  Oral Oncol. 2001;  37 211-215
• 18 Morris J C, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk.  Mol Ther. 2000;  1 56-62
• 19 Wollenberg B, Kastenbauer E, Mundl H, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Löhrs U, Naujoks K, Rollston R. Gene therapyphase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol.  Hum Gene Ther. 1999;  10 141-147
• 20 Wollenberg B, Lang S, Friess T, Naujoks K, Mayer A, Kastenbauer E, Zeidler R. (Induction of antitumor immune response in the mouse model after vaccination with B7.1 expressing tumor cells).  Laryngorhinootologie. 1999;  78 36-40
• 21 He Y, Zeng Q, Drenning S D, Melhem M F, Tweardy D J, Huang L, Grandis J R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.  J Natl Cancer Inst. 1998;  90 1080-1087
• 22 Riedel F, Gotte K, Li M, Hormann K, Grandis J R. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.  Int J Oncol. 2002;  21 11-16
• 23 Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse H J, Hollweck G, Hislop A D, Blake N, Croom-Carter D, Wollenberg B, Moss P A, Zeidler R, Rickinson A B, Hammerschmidt W. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.  Blood. 2002;  100 1755-1764
• 24 Jin X, Bookstein R, Wills K, Avanzini J, Tsai V, LaFace D, Terracina G, Shi B, Nielsen L L. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo.  Cancer Gene Ther. 2001;  8 982-989
• 25 Kleinman H K, Liau G, He Y, Zeng Q, Drenning S D, Melhem M F, Tweardy D J, Huang L, Grandis J R. Gene therapy for antiangiogenesis (interference with EGFR expression, using an antisense-based gene therapy approach, may be an effective means of treating EGFR-overexpressing tumors, including SCCHN).  J Natl Cancer Inst. 2001;  93 965-967